Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

NCT02979431 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Interventions

BIOLOGICAL: ALX-0171 3.0 mg/kg
BIOLOGICAL: ALX-0171 6.0 mg/kg
BIOLOGICAL: ALX-0171 9.0 mg/kg
OTHER: Placebo

Sponsor

Ablynx, a Sanofi company